Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance
NCT ID: NCT00847899
Last Updated: 2009-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
150 participants
INTERVENTIONAL
2009-01-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AR9281
AR9281
AR9281 taken in BID dosing regimen for 28 days
2
AR9281
AR9281
AR9281 taken in TID dosing regimen for 28 days
3
Placebo
Placebo
Placebo taken in BID dosing regimen for 28 days
4
Placebo
Placebo
Placebo taken in TID dosing regimen for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AR9281
AR9281 taken in BID dosing regimen for 28 days
AR9281
AR9281 taken in TID dosing regimen for 28 days
Placebo
Placebo taken in BID dosing regimen for 28 days
Placebo
Placebo taken in TID dosing regimen for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* naive to antihypertensive medication or on two or less antihypertensive medications
* impaired glucose tolerance
* mild obesity
Exclusion Criteria
* History of severe heart failure
* AST, ALT levels more than twice the normal range
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arete Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arete Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arete Investigational site
Mobile, Alabama, United States
Arete Investigational site
Muscle Shoals, Alabama, United States
Arete Investigational site
Anaheim, California, United States
Arete Investigational site
Concord, California, United States
Arete Investigational site
Mission Hills, California, United States
Arete Investigational site
Bradenton, Florida, United States
Arete Investigational site
DeLand, Florida, United States
Arete Investigational site
Jacksonville, Florida, United States
Arete Investigational site
Largo, Florida, United States
Arete Investigational site
Miami, Florida, United States
Arete Investigational site
New Port Richey, Florida, United States
Arete Investigational site
Pembroke Pines, Florida, United States
Arete Investigational site
Port Orange, Florida, United States
Arete Investigational site
Tampa, Florida, United States
Arete Investigational site
Marietta, Georgia, United States
Arete Investigational site
Addison, Illinois, United States
Arete Investigational site
Louisville, Kentucky, United States
Arete Investigational site
Brockton, Massachusetts, United States
Arete Investigational site
Paw Paw, Michigan, United States
Arete Investigational site
Las Vegas, Nevada, United States
Arete Investigational site
Cincinnati, Ohio, United States
Arete Investigational site
Cincinnati, Ohio, United States
Arete Investigational site
Marion, Ohio, United States
Arete investigational site
Mount Gilead, Ohio, United States
Arete Investigational site
Oklahoma City, Oklahoma, United States
Arete Investigational site
Eugene, Oregon, United States
Arete Investigational site
Austin, Texas, United States
Arete Investigational site
Dallas, Texas, United States
Arete Investigational site
San Antonio, Texas, United States
Arete Investigational site
Orem, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Arete Therapeutics home website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AR9281-CLN-003
Identifier Type: -
Identifier Source: org_study_id